

Elizabeth C Smyth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4629902/publications.pdf>

Version: 2024-02-01

32
papers

4,506
citations

623188

14
h-index

433756

31
g-index

34
all docs

34
docs citations

34
times ranked

5040
citing authors

#	ARTICLE	IF	CITATIONS
1	Low Programmed Death-Ligand 1â€‘Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 392-402.	0.8	87
2	Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy. <i>BioDrugs</i> , 2022, 36, 473-485.	2.2	5
3	Anti-cancer therapy with cyclin-dependent kinase inhibitors: impact and challenges. <i>Expert Reviews in Molecular Medicine</i> , 2021, 23, e6.	1.6	10
4	Chemoradiotherapy or Surgery for Very Early Esophageal Squamous Cancer: Can a Nonrandomized Trial Give Us the Answer?. <i>Gastroenterology</i> , 2021, 161, 1793-1795.	0.6	2
5	Dissecting Response and Resistance to Antiâ€‘PD-1 Therapy in Microsatellite-Unstable Gastric Cancer. <i>Cancer Discovery</i> , 2021, 11, 2126-2128.	7.7	1
6	27 years of stomach cancer: painting a global picture. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 5-6.	3.7	13
7	Modulation of Biliary Cancer Chemoâ€‘Resistance Through MicroRNAâ€‘Mediated Rewiring of the Expansion of CD133+ Cells. <i>Hepatology</i> , 2020, 72, 982-996.	3.6	30
8	Biomarkers for Precision Treatment in Gastric Cancer. <i>Visceral Medicine</i> , 2020, 36, 364-372.	0.5	14
9	Gastric cancer. <i>Lancet, The</i> , 2020, 396, 635-648.	6.3	2,084
10	A global perspective on oesophageal cancer: two diseases in one. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 521-522.	3.7	9
11	Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers. <i>Frontiers in Oncology</i> , 2020, 10, 763.	1.3	32
12	Multimodality treatment for localized gastric cancer: state of the art and new insights. <i>Current Opinion in Oncology</i> , 2020, 32, 347-355.	1.1	19
13	Chemotherapy for resectable microsatellite instability-high gastric cancer?. <i>Lancet Oncology, The</i> , 2020, 21, 204.	5.1	27
14	Anti-EGFR plus chemotherapy in unselected advanced oesophageal squamous cell carcinoma: less POWERful than expected. <i>Annals of Oncology</i> , 2020, 31, 161-162.	0.6	1
15	Progress and challenges in gastroesophageal cancer. <i>Current Problems in Cancer</i> , 2020, 44, 100590.	1.0	5
16	Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro-oesophageal junction. <i>British Journal of Surgery</i> , 2019, 106, 1204-1215.	0.1	6
17	ctDNA in Gastric and Gastroesophageal Cancer: Prognostic, Predictive, or Preliminary?. <i>Clinical Cancer Research</i> , 2019, 25, 6893-6895.	3.2	4
18	More is not always better: triplet chemotherapy and advanced gastric cancer. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 490-491.	3.7	2

#	ARTICLE	IF	CITATIONS
19	Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer. <i>Drugs</i> , 2019, 79, 1-10.	4.9	18
20	MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. <i>Gastroenterology</i> , 2018, 154, 1066-1079.e5.	0.6	94
21	Peri-operative therapy for operable gastroesophageal adenocarcinoma: past, present and future. <i>Annals of Oncology</i> , 2018, 29, 1377-1385.	0.6	13
22	MUC16 Mutations and Prognosis in Gastric Cancer. <i>JAMA Oncology</i> , 2018, 4, 1698.	3.4	4
23	Pembrolizumab versus paclitaxel in gastro-oesophageal adenocarcinoma. <i>Lancet</i> , The, 2018, 392, 97-98.	6.3	5
24	Genomic loss of heterozygosity and survival in the REAL3 trial. <i>Oncotarget</i> , 2018, 9, 36654-36665.	0.8	13
25	Mismatch Repair Deficiency, Microsatellite Instability, and Survival. <i>JAMA Oncology</i> , 2017, 3, 1197.	3.4	398
26	Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2/3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 357-370.	5.1	244
27	Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma – Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e244.	5.1	1
28	Oesophageal cancer. <i>Lancet</i> , The, 2017, 390, 2383-2396.	6.3	796
29	Missing a GOLDen opportunity in gastric cancer. <i>Lancet Oncology</i> , The, 2017, 18, 1561-1563.	5.1	11
30	High-Level Clonal <i>FGFR</i> Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. <i>Cancer Discovery</i> , 2016, 6, 838-851.	7.7	222
31	Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2721-2727.	0.8	214
32	A prospective evaluation of the utility of ¹⁸ F-fluoro- ¹⁸ F-deoxy- ¹⁸ F-fluoro- ¹⁸ F-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. <i>Cancer</i> , 2012, 118, 5481-5488.	2.0	122